Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1422142/000156459018013535/arpo-10q_20180331.htm
SEC Filings
ARPO Annual Reports
10-K Annual Report March 2021
10-K Annual Report March 2020
10-K Annual Report March 2019
10-K Annual Report March 2018
10-K Annual Report March 2017
10-K Annual Report March 2016
10-K Annual Report February 2015
10-K Annual Report March 2014
10-K Annual Report March 2013
10-K Annual Report March 2012
10-K Annual Report March 2021
10-K Annual Report March 2020
10-K Annual Report March 2019
10-K Annual Report March 2018
10-K Annual Report March 2017
10-K Annual Report March 2016
10-K Annual Report February 2015
10-K Annual Report March 2014
10-K Annual Report March 2013
10-K Annual Report March 2012
ARPO Quarterly Reports
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report November 2019
10-Q Quarterly Report August 2019
10-Q Quarterly Report May 2019
10-Q Quarterly Report November 2018
10-Q Quarterly Report August 2018
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report November 2019
10-Q Quarterly Report August 2019
10-Q Quarterly Report May 2019
10-Q Quarterly Report November 2018
10-Q Quarterly Report August 2018
ARPO Corporate News
Bylaw Change
Change in Assets
Change in Control
Code of Ethics Change
Event for Officers
Financial Exhibit
New Agreement
Security Holders Change
Unregistered Sales August 2021
Financial Exhibit
New Agreement August 2021
Vote of Security Holders August 2021
Earnings Release
Financial Exhibit August 2021
Financial Exhibit
Regulated Disclosure
Vote of Security Holders July 2021
Financial Exhibit
Regulated Disclosure June 2021
Earnings Release
Financial Exhibit May 2021
Bylaw Change
Change in Control
Event for Officers
Financial Exhibit
New Agreement
Regulated Disclosure
Unregistered Sales May 2021
Event for Officers
Financial Exhibit April 2021
Earnings Release
Financial Exhibit March 2021
Bylaw Change
Change in Assets
Change in Control
Code of Ethics Change
Event for Officers
Financial Exhibit
New Agreement
Security Holders Change
Unregistered Sales
Change in Assets
Change in Control
Code of Ethics Change
Event for Officers
Financial Exhibit
New Agreement
Security Holders Change
Unregistered Sales
August 2021
Financial Exhibit
New Agreement
New Agreement
August 2021
Vote of Security Holders
August 2021
Earnings Release
Financial Exhibit
Financial Exhibit
August 2021
Financial Exhibit
Regulated Disclosure
Vote of Security Holders
Regulated Disclosure
Vote of Security Holders
July 2021
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
June 2021
Earnings Release
Financial Exhibit
Financial Exhibit
May 2021
Bylaw Change
Change in Control
Event for Officers
Financial Exhibit
New Agreement
Regulated Disclosure
Unregistered Sales
Change in Control
Event for Officers
Financial Exhibit
New Agreement
Regulated Disclosure
Unregistered Sales
May 2021
Event for Officers
Financial Exhibit
Financial Exhibit
April 2021
Earnings Release
Financial Exhibit
Financial Exhibit
March 2021
Last10K.com | 10-Q Quarterly Report Tue May 15 2018
Exhibit 99.1
Aerpio Reports First Quarter 2018 Financial Results and Provides Company Update
TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track
CINCINNATI—(BUSINESS WIRE)— Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the first quarter ended March 31, 2018.
Stephen Hoffman, M.D. Ph.D., Chief Executive Officer of Aerpio, commented, “We are pleased that TIME-2b, our ongoing Phase 2b study in patients with non-proliferative diabetic retinopathy (NPDR), is fully enrolled ahead of schedule. This study will evaluate the effect of daily AKB-9778, our first-in-class Tie2-activator, to improve the diabetic retinopathy severity score by two-steps or greater versus a placebo control after 48 weeks of treatment. We will also assess the number of patients that progress to diabetic macular edema and proliferative diabetic retinopathy, and kidney function as key secondary endpoints. We expect to report top-line data from the TIME-2b study in the second quarter of 2019.”
Dr. Hoffman added, “In addition to our lead development program for NPDR, we continue to advance our earlier pipeline programs, a topical formulation of AKB-9778 in glaucoma and AKB-4924, our first-in-class HIF-1α stabilizer, in inflammatory bowel disease. We are looking forward to multiple clinical milestones over the next twelve months.”
Recent Company Highlights
| • | Completed enrollment in the TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of the Company’s lead candidate, AKB-9778, for patients with moderate-to-severe NPDR. |
| • | Presented top-line renal function data from the Company’s Phase 2a TIME-2 clinical trial at the Keystone Symposium on Reducing the Burden of Diabetes Related End-Organ Injury in February 2018. |
| • | Completed a pre-IND meeting with the U.S. Food and Drug Administration (FDA) for AKB-4924, a once-daily, oral HIF-1α stabilizer for treatment of ulcerative colitis, a form of |
The following information was filed by Aerpio Pharmaceuticals, Inc. (ARPO) on Tuesday, May 15, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Aerpio Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Aerpio Pharmaceuticals, Inc..
Assess how Aerpio Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy
Aerpio Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Document And Entity Information
Condensed Consolidated Balance Sheets (parenthetical) (unaudited)
Condensed Consolidated Balance Sheets (unaudited)
Condensed Consolidated Statements Of Operations And Comprehensive Loss (unaudited)
Consolidated Statement Of Stockholders' Equity
Consolidated Statements Of Cash Flows (unaudited)
Accounts Payable And Accrued Expenses
Accounts Payable And Accrued Expenses (tables)
Accounts Payable And Accrued Expenses - Schedule Of Accounts Payable And Accrued Expenses (details)
Commitments And Contingencies
Commitments And Contingencies (tables)
Commitments And Contingencies - Additional Information (detail)
Commitments And Contingencies - Schedule Of Future Payments Related To Operating Leases (detail)
Common Stock
Common Stock - Additional Information (detail)
Employee Stock Purchase Plan
Employee Stock Purchase Plan - Additional Information (detail)
Income Taxes
Income Taxes - Additional Information (detail)
Nature Of Organization And Operations
Nature Of Organization And Operations - Additional Information (detail)
Net Loss Per Share Attributable To Common Stockholders
Net Loss Per Share Attributable To Common Stockholders (tables)
Net Loss Per Share Attributable To Common Stockholders - Schedule Of Computation Of Basic And Diluted Net Loss Per Share (detail)
Net Loss Per Share Attributable To Common Stockholders - Schedule Of Weighted Average Common Stock Equivalents Excluded From Calculation Of Diluted Net Loss Per Share (detail)
Notes Payable To Investors
Notes Payable To Investors - Additional Information (detail)
Preferred Stock
Preferred Stock - Additional Information (detail)
Stock-based Compensation
Stock-based Compensation (tables)
Stock-based Compensation - Additional Information (detail)
Stock-based Compensation - Summary Of Recognized Compensation Cost Related To Employee And Non-employee Stock-based Compensation Activity (detail)
Stock-based Compensation - Summary Of Restricted Stock Activity (detail)
Stock-based Compensation - Summary Of Stock Option Activity (detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Additional Information (detail)
Summary Of Significant Accounting Policies - Schedule Of Assets Measured On Recurring Basis (detail)
Material Contracts, Statements, Certifications & more
Aerpio Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ARPO
CIK: 1422142
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-18-013535
Submitted to the SEC: Tue May 15 2018 9:09:46 AM EST
Accepted by the SEC: Tue May 15 2018
Period: Saturday, March 31, 2018
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
SEC.gov
Bookmark the Permalink: https://last10k.com/sec-filings/arpo/0001564590-18-013535.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...